In the SELECT trial that included over 17,000 patients with obesity and established CV disease, but without diabetes, weekly s.c
All doses of orforglipron in the ATTAIN-2 trial demonstrated a dose-dependent reduction in body weight and HbA1c at 72 weeks, Nasreen Alfaris , MD, MPH, consultant at the Obesity, Endocrine and Metabolism Center at King Fahad Medical City in Riyadh, Saudi Arabia, said during a presentation
Initial weight loss typically occurs within the first month, with ongoing, steady progress over the following months
We invite you to discuss the potential of GLP-1 medications and explore how they can be integrated into your personalized diabetes management plan
A board-certified health coach is included
Should I take levothyroxine before or after semaglutide